^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Small Cell Lung Cancer
    Drug:cisplatin (DNA synthesis inhibitor) +
    etoposide IV (Topoisomerase II inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Published date:
    04/14/2021
    Excerpt:
    Recommendations: The preferred ChT for patients with limited-stage (stage I-III) SCLC is cisplatin plus etoposide [I, A].
    DOI:
    10.1016/j.annonc.2021.03.207